Monovalent norovirus Vaccine (Vaxart)/VXA-G2-4-NS

N/A

Report date: 2024/01/08 17:08:37

Base Information

Drug NameMonovalent norovirus Vaccine (Vaxart)/VXA-G2-4-NS

Drug Alias NameNorovirus Bivalent Vaccine(Vaxart)VXA-NVV-201

ClassificationVaccines > Vaccine type > Multivalent vaccineVaccines > Application > Prophylactic vaccineVaccines > Biological material > Viral vaccine

Mechanisms of ActionImmunostimulantsToll like receptor 3 agonists

TargetsToll like receptor 3

Therapy Area/IndicationsNorovirus Infections

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsYes Monovalent norovirus Vaccine (Vaxart)VXA-G2-4-NS

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesVaxart Inc

China Registration ClassN/A

Develop Information

Active CompaniesVaxart Inc

Inactive CompaniesN/A

Active IndicationsNorovirus Infections

Inactive IndicationsN/A

Other Information

ATC CodeN/A